Medial Temporal Lobe Atrophy in Down Syndrome Along the Alzheimer’s Disease Continuum The medial temporal lobe (MTL) is one of the first regions affected by tau pathology, making structural changes in these areas promising biomarkers for identifying early signs of Alzheimer’s disease (AD). However, little is known about the integrity of these regions in individuals … Read more
Alzheimer’s Disease, Down Syndrome and GFAP People with Down syndrome are at higher risk of developing Alzheimer’s disease than the general population. In fact, by the age of 70, more than 95% of people with Down syndrome will develop Alzheimer’s disease, which is the leading cause of death in this population. This strong association is … Read more
Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid or using positron emission tomography (PET). Yet, these methods are either invasive or expensive and not easily accessible to all … Read more
Alzheimer’s disease is the major cause of death in adults with Down syndrome. Thus, there is an urgent need for objective biomarkers that can improve early diagnosis and monitor progression of Alzheimer’s disease in the Down syndrome population. Our recent study, entitled “Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction … Read more